Catalysis Science & Technology
Paper
¨
12 A. Preetz, H.-J. Drexler, C. Fischer, Z. Dai, A. Borner,
Notes and references
W. Baumann, A. Spannenberg, R. Thede and D. Heller,
Chem.–Eur. J., 2008, 14, 1445–1451.
13 H.-J. Drexler, S. Zhang, A. Sun, A. Spannenberg, A. Arrieta,
A. Preetz and D. Heller, Tetrahedron: Asymmetry, 2004, 15,
2139–2150.
1 (a) W. S. Knowles and M. J. Sabacky, J. Chem. Soc., Chem.
Commun., 1968, 1445–1446; (b) H. B. Kagan and T. P. Dang,
J. Am. Chem. Soc., 1972, 94, 6429–6433; (c) Y. Chi, W. Tang
and X. Zhang, in Modern Rhodium-Catalyzed Organic Reac-
tions, ed. P. A. Evans, Wiley-VCH, Weinheim, 2005, ch. 1,
pp. 1–31 and references cited therein.
2 J. Halpern, D. P. Riley, A. S. C. Chan and J. J. Pluth, J. Am.
Chem. Soc., 1977, 99, 8055–8057.
3 A. Preetz, W. Baumann, H.-J. Drexler, C. Fischer, J. Sun,
A. Spannenberg, O. Zimmer, W. Hell and D. Heller,
Chem.–Asian J., 2008, 3, 1979–1982.
4 (a) C. Fischer, C. Kohrt, H.-J. Drexler, W. Baumann and
D. Heller, Dalton Trans., 2011, 40, 4162–4166; (b) J. Vicente,
J. Gil-Rubio, D. Bautista, A. Sironi and N. Masciocchi, Inorg.
Chem., 2004, 43, 5665–5675; (c) M. Ebihara, M. Iiba,
S. Higashi, N. Tsuzuki, T. Kawamura, T. Morioka,
S. Ozawa, T. Yamabe and H. Masuda, Polyhedron, 2003,
22, 3413–3422; (d) N. Kuhn, M. Grathewohl, C. Nachtigal
and M. Steinmann, Z. Anorg. Allg. Chem., 2001, 627,
2039–2041; (e) H. Seino, Y. Mizobe and M. Hidai, Organo-
metallics, 2000, 19, 3631–3639; ( f ) A. V. de Miguel, K. Isobe,
P. M. Bailey, N. J. Meanwell and P. M. Maitlis, Organo-
metallics, 1982, 1, 1604–1607.
14 A. Meißner, A. Preetz, H.-J. Drexler, W. Baumann,
¨
A. Spannenberg, A. Konig and D. Heller, in preparation.
15 The dinuclear complex is very soluble in THF, however
scarcely soluble in MeOH. Vice versa, the trinuclear complex
is more soluble in MeOH than in THF.
16 A. Preetz, W. Baumann, C. Fischer, H.-J. Drexler, T. Schmidt,
R. Thede and D. Heller, Organometallics, 2009, 28, 3673–3677.
17 All attempts to isolate [Rh3(t-Bu-BisP*)3(m3-Cl)2][BF4] from
the reaction of the solvate complex with NaCl failed.
However, we succeeded while trying to isolate the product
complex [Rh(t-Bu-BisP*)(macH2)][BF4] from CH2Cl2: the
hydrogenation product of mac was added to the solvate
MeOH complex. The solvent was removed in vacuo and the
remaining solid was redissolved in CH2Cl2 and layered with
diethyl ether. After a few days single crystals of [Rh3(t-Bu-
BisP*)3(m3-Cl)2][BF4] suitable for X-ray analysis crystallized.
18 C. Kohrt, S. Hansen, H.-J. Drexler, U. Rosenthal, A. Schulz
and D. Heller, Inorg. Chem., 2012, 51, 7377–7383.
19 The molecular structure of the trinuclear complex obtained
in a different way is shown in Fig. S8, ESI†.
5 T. Yamagata, K. Tani, Y. Tatsuno and T. Saito, J. Chem. Soc.,
Chem. Commun., 1988, 466–468.
20 The m3-bridges of the trinuclear complex are disordered
(population: 0.6 Cl, 0.4 Br). The only Cl source can be the
solvent CH2Cl2 from which the complex was recrystallized.
Only one of the four possible populations is shown.
21 C. R. Landis and J. Halpern, J. Am. Chem. Soc., 1987, 109,
1746–1754.
22 The asymmetric hydrogenation of dimethyl itaconate as
well as the structure and stability of the catalyst–substrate
complex with the DIPAMP system are described in
6 A. Preetz, C. Fischer, C. Kohrt, H.-J. Drexler, W. Baumann
and D. Heller, Organometallics, 2011, 30, 5155–5159.
7 From the hydrogenation product the THP ether of the
4-amino-2(R)-methylbutan-1-ol, an important intermediate
towards the receptor antagonist TAK-637, can be
synthesized.
8 C. J. Cobley, I. C. Lennon, C. Praquin and A. Zanotti-Gerosa,
Org. Process Res. Dev., 2003, 7, 407–411.
9 (a) D. J. Ager, A. H. M. de Vries and J. G. de Vries, Chem. Soc.
Rev., 2012, 41, 3340–3380; (b) C. A. Busacca, D. R. Fandrick,
J. J. Song and C. H. Senanayake, Adv. Synth. Catal., 2011,
353, 1825–1864.
¨
T. Schmidt, Z. Dai, H.-J. Drexler, W. Baumann, C. Jager,
D. Pfeifer and D. Heller, Chem.–Eur. J., 2008, 14, 4469–4471.
23 (a) J. M. Buriak, J. C. Klein, D. G. Herrington and J. A.
Osborn, Chem.–Eur. J., 2000, 6, 139–150; (b) K. G. Moloy and
J. L. Petersen, Organometallics, 1995, 14, 2931–2936.
24 The prochiral olefin (Z)-3-[1-(dimethylamino)-2-methylpent-
2-en-3-yl]phenol is also an important precursor of the new
analgesic drug Tapentadol which is as an open-chain
analogue of Tramadol. The chirality of the new stereogenic
centers is very important for the pharmacological effect. The
(R,R) stereoisomer of Tapentadol is a novel, centrally acting
analgesic with a dual mode of action: m-opioid receptor
(MOR) agonism and norepinephrine reuptake inhibition.
Tapentadol is the first oral centrally acting analgesic to be
approved in 2008 in the United States for more than a
decade. The corresponding (S,S) enantiomer is a very strong
opioid. The (R,S) or (S,R) stereoisomers have no analgesic
effect.
10 [2-(3-Methoxy-phenyl)-cyclohex-1-enylmethyl]-dimethylamine
is a member of a class of 1,2-disubstituded cyclohexene
derivatives which are important intermediates in the
synthesis of pharmaceutically active compounds acting on
the central nervous system. The challenge is the establish-
ment of the desired relative and absolute stereochemistry of
two new stereogenic centers responsible for the pharmaco-
logical effect. [2-(3-Methoxy-phenyl)-cyclohex-1-enylmethyl]-
dimethylamine can be transformed by a stereoselective
hydrogenation to Tramadol, an important analgesic drug
used world-wide.
11 Elemental analysis of a saturated NaCl solution in methanol
showed that in 1.0 mL MeOH ca. 7 mg of NaCl can be
dissolved, which corresponds to 0.12 mmol. 105 mg NaBr
(1.0 mmol) and 496 mg NaI (3.3 mmol) can be dissolved in 25 G. M. Sheldrick, Acta Crystallogr., Sect. A: Found. Crystallogr.,
1.0 mL MeOH.
1997, 64, 112–122.
c
This journal is The Royal Society of Chemistry 2013
468 Catal. Sci. Technol., 2013, 3, 462--468